Journal article

Interleukin-6 and total antioxidant capacity levels following N-acetylcysteine and a combination nutraceutical intervention in a randomised controlled trial for bipolar disorder

CC Bortolasci, C Voigt, A Turner, M Mohebbi, L Gray, S Dodd, K Walder, M Berk, SM Cotton, GS Malhi, CH Ng, N Dowling, J Sarris, OM Dean

Acta Neuropsychiatrica | CAMBRIDGE UNIV PRESS | Published : 2020

Abstract

OBJECTIVE: The aims of this study were to evaluate changes in inflammatory and oxidative stress levels following treatment with N-acetylcysteine (NAC) or mitochondrial-enhancing agents (CT), and to assess the how these changes may predict and/or moderate clinical outcomes primarily the Montgomery-Åsberg Depression Rating Scale (MADRS). METHODS: This study involved secondary analysis of a placebo-controlled randomised trial (n = 163). Serum samples were collected at baseline and week 16 of the clinical trial to determine changes in Interleukin-6 (IL-6) and total antioxidant capacity (TAC) following adjunctive CT and/or NAC treatment, and to explore the predictability of the outcome or moderat..

View full abstract

Grants

Awarded by National Health & Medical Research Council (NHMRC) Senior Principal Research Fellowship


Awarded by NHMRC


Awarded by Wright Biomedical Research Fellowship


Funding Acknowledgements

CCB is supported by an Alfred Deakin Postdoctoral Research Fellowship. MB is supported by a National Health & Medical Research Council (NHMRC) Senior Principal Research Fellowship (1059660). SMC is supported by a NHMRC Senior Research Fellowship (APP1136344). OMD is an R.D. Wright Biomedical Research Fellowship (APP1145634) and JS is supported by an NHMRC Clinical Research Fellowship (APP1125000).